Does Rallies show Form 4 insider transactions for MED?

Yes. Rallies tracks MED insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MED research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MED. It does not provide personalized investment advice.

MED (Medifast, Inc.) Stock Analysis - Insider Trades

Medifast, Inc. (MED) is a publicly traded Consumer Cyclical sector company. As of May 21, 2026, MED trades at $12.62 with a market cap of $138.43M and a P/E ratio of -6.95. MED moved -0.28% today. Year to date, MED is +15.07%; over the trailing twelve months it is -9.61%. Its 52-week range spans $9.22 to $21.98. Analyst consensus is neutral with an average price target of $12.00. Rallies surfaces MED's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MED stock inside the company?

Recent MED insider activity includes SCHLACKMAN SCOTT bought 2.50K, SCHLACKMAN SCOTT bought 2.50K, Chard Daniel R bought 17.68K, Chard Daniel R bought 381, and SCHLACKMAN SCOTT sold 1.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MED Key Metrics

Key financial metrics for MED
Metric	Value
Price	$12.62
Market Cap	$138.43M
P/E Ratio	-6.95
EPS	$-1.82
Dividend Yield	1.65%
52-Week High	$21.98
52-Week Low	$9.22
Volume	10
Avg Volume	0
Revenue (TTM)	$346.10M
Net Income	$-20.02M
Gross Margin	70.12%

Recent MED Insider Trades

SCHLACKMAN SCOTT bought 2.50K (~$31.32K) on May 11, 2026.
SCHLACKMAN SCOTT bought 2.50K (~$31.63K) on May 8, 2026.
Chard Daniel R bought 17.68K (~$178.72K) on Mar 20, 2026.
Chard Daniel R bought 381 (~$5.00K) on Jun 13, 2025.
SCHLACKMAN SCOTT sold 1.30K (~$51.23K) on Mar 8, 2024.

Latest MED News

Medifast’s Optavia Cuts Visceral Fat by 14% While Preserving 98% Lean Mass — May 15, 2026
Medifast Gains HSA/FSA Reimbursement for OPTAVIA and Pushes New Metabolic Systems — Mar 10, 2026
Medifast Gains Zacks Rank #2, Sees 30.5% Earnings Growth Forecast — Mar 6, 2026
Diageo H1 Sales Fall 4% to $10.5B; EPS Declines 2.5% — Feb 26, 2026
Medifast Reports 36.9% Q4 Revenue Decline, $18.1M Net Loss, Boosts Coach Productivity — Feb 19, 2026

MED Analyst Consensus

1 analysts cover MED: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $12.00.

Common questions about MED

Who is trading MED stock inside the company?: Recent MED insider activity includes SCHLACKMAN SCOTT bought 2.50K, SCHLACKMAN SCOTT bought 2.50K, Chard Daniel R bought 17.68K, Chard Daniel R bought 381, and SCHLACKMAN SCOTT sold 1.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MED?: Yes. Rallies tracks MED insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MED research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MED. It does not provide personalized investment advice.